메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 25, Issue 25, 2007, Pages 4021-4023
In reply [3]
Author keywords

[No Author keywords available]
Indexed keywords

GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;
EID: 34748870758     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.4363     Document Type: Letter
Times cited : (8)
References (9)
  • 1
    • 33847147313 scopus 로고    scopus 로고
    • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    • Wolff AC, Hammond MEH, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 118-145
    • Wolff, A.C.1    Hammond, M.E.H.2    Schwartz, J.N.3
  • 2
    • 33846568336 scopus 로고    scopus 로고
    • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    • Epub ahead of print
    • Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18, 2007 [Epub ahead of print]
    • (2007) Arch Pathol Lab Med , vol.131 , pp. 18
    • Wolff, A.C.1    Hammond, M.E.2    Schwartz, J.N.3
  • 3
    • 0347539778 scopus 로고    scopus 로고
    • Calibration of immunohistochemistry for assessment of HER2 in breast cancer: Results of the French multicentre GEFPICS study
    • Vincent-Salomon A, MacGrogan G, Couturier J, et al: Calibration of immunohistochemistry for assessment of HER2 in breast cancer: Results of the French multicentre GEFPICS study. Histopathology 42:337-347, 2003
    • (2003) Histopathology , vol.42 , pp. 337-347
    • Vincent-Salomon, A.1    MacGrogan, G.2    Couturier, J.3
  • 4
    • 0034473776 scopus 로고    scopus 로고
    • The role of HER-2 expression in predicting response to therapy in breast cancer
    • discussion 92-100
    • Mass R: The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 27:46-52; discussion 92-100, 2000
    • (2000) Semin Oncol , vol.27 , pp. 46-52
    • Mass, R.1
  • 5
    • 0035873962 scopus 로고    scopus 로고
    • Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
    • Tubbs RR, Pettay JD, Roche PC, et al: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19:2714-2721, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 2714-2721
    • Tubbs, R.R.1    Pettay, J.D.2    Roche, P.C.3
  • 6
    • 0036161321 scopus 로고    scopus 로고
    • HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
    • Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-154, 2002
    • (2002) Mayo Clin Proc , vol.77 , pp. 148-154
    • Perez, E.A.1    Roche, P.C.2    Jenkins, R.B.3
  • 7
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
    • Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med 353:1673-1684, 2005
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 8
    • 33845914783 scopus 로고    scopus 로고
    • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial
    • Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007
    • (2007) Lancet , vol.369 , pp. 29-36
    • Smith, I.1    Procter, M.2    Gelber, R.D.3
  • 9
    • 84871470085 scopus 로고    scopus 로고
    • Herceptin Package Insert November 2006, Genentech Inc, South San Francisco, CA, 2006
    • Herceptin Package Insert (November 2006). Genentech Inc, South San Francisco, CA, 2006. http://www.gene.com/gene/products/information/oncology/ herceptin/insert.jsp

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.